Citigroup and Bank of America issued rating updates for Acadia Pharmaceuticals, alongside insider news regarding James Kihara.
12 reports, 2 independent
Updated Sat 00:00
Mostly repetition
- Reports
- 12
- Developments
- 2
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup and Bank of America issued rating updates for Acadia Pharmaceuticals, alongside insider news regarding James Kihara.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BofA reaffirmed buy rating and Morgan Stanley raised target price on Acadia.1 source
Bank of America raised Acadia Pharmaceuticals rating; Citigroup restated buy rating.1 source
Keep exploring
The entities involved
-
Acadia Pharmaceuticals
Pharmaceutical company, which developed Nuplazid, based in San Diego, California.
-
Citigroup
American investment bank and financial services corporation
-
Bank of America
American multinational banking and financial services corporation
Related events
- Citigroup reiterated a market perform rating, Bank of America restated an underperform rating, and Raymond James Financial started coverage for Omega Healthcare Investors, Inc.
- Citigroup boosted its price target and gave a buy rating for Wholesale Club, with MarketBeat providing consensus data.
- Citigroup lifted its price target and gave a buy rating for Timken Company, with MarketBeat providing consensus data.
- Citigroup raised its rating on Innate Pharma stock, which trades on the Nasdaq exchange. Leerink Partners also upgraded the rating. MarketBeat aggregates the rating data.
- Benchmark initiated coverage with a buy rating, while MarketBeat provided consensus data and Citigroup reduced its target price.